

ARENA PHARMACEUTICALS INC
Form S-3MEF
December 07, 2006

[QuickLinks](#) -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on December 7, 2006

Registration No. 333-

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

ARENA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

23-2908305
(I.R.S. Employer Identification No.)

**6166 Nancy Ridge Drive
San Diego, California 92121
(858) 453-7200**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Steven W. Spector, Esq.
Senior Vice President, General Counsel and Secretary
6166 Nancy Ridge Drive
San Diego, California 92121
(858) 453-7200**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:
**Steven M. Przesmicki, Esq.
Cooley Godward LLP
4401 Eastgate Mall
San Diego, California 92121
(858) 550-6000**

Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this Registration Statement.

If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.

Edgar Filing: ARENA PHARMACEUTICALS INC - Form S-3MEF

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. 333-137030

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.

Calculation of Registration Fee

Title of Class of Securities to be Registered	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee(1)
Common Stock, par value \$.0001 per share, including related rights to purchase Series A Junior Participating Preferred Stock	\$9,577,250.00	\$1,024.77

(1) Calculated pursuant to rule 457(o) under the Securities Act.

EXPLANATORY NOTE

This registration statement is being filed to register an additional \$9,577,250.00 worth of shares of our common stock, par value \$.0001, pursuant to Rule 462(b) of the Securities Act of 1933, as amended. In accordance with Rule 462(b), this registration statement incorporates by reference the contents of our registration statement on Form S-3 (File No. 333-137030) which was declared effective on September 12, 2006, including all amendments, supplements and exhibits thereto and all information incorporated by reference therein, other than the exhibits included herein.

The required opinions and consents are listed on the Exhibit Index attached to and filed with this registration statement.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on December 7, 2006.

ARENA PHARMACEUTICALS, INC.

By: /s/ STEVEN W. SPECTOR

Steven W. Spector, Senior Vice President, General Counsel and Secretary

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Date
By: /s/ * _____ Jack Lief, Chief Executive Officer and Director (Principal Executive Officer)	December 7, 2006
By: /s/ * _____ Robert E. Hoffman, CPA, Vice President, Finance and Chief Financial Officer (Principal Financial and Accounting Officer)	December 7, 2006
By: /s/ * _____ Dominic P. Behan, Ph.D., Director	December 7, 2006
By: /s/ * _____ Donald D. Belcher, Director	December 7, 2006
By: /s/ * _____ Scott H. Bice, J.D., Director	December 7, 2006
By: /s/ * _____ Harry F. Hixson, Jr., Ph.D., Director	December 7, 2006
By: /s/ * _____ J. Clayburn La Force Jr., Ph.D., Director	December 7, 2006
By: /s/ * _____ Louis J. Lavigne, Jr., Director	December 7, 2006
By: /s/ * _____ Tina S. Nova, Ph.D., Director	December 7, 2006
By: /s/ * _____	December 7, 2006

Edgar Filing: ARENA PHARMACEUTICALS INC - Form S-3MEF

Signature

Date

Christine A. White, M.D., Director

***By:** /s/ STEVEN W. SPECTOR

Steven W. Spector
Attorney-in-fact

INDEX TO EXHIBITS

Exhibit Number	Description of Document
1.1	Form of Underwriting Agreement (to be filed as an exhibit to a Current Report of the registrant on Form 8-K and incorporated herein by reference)
5.1	Opinion of Cooley Godward Kronish LLP
23.1	Consent of Cooley Godward Kronish LLP (included as Exhibit 5.1 to this filing)
23.2	Consent of Independent Registered Public Accounting Firm
24.1	Power of Attorney(1)

(1)

Previously filed on the signature page to Registrant's registration statement on Form S-3 (No. 333-137030), filed with the Securities and Exchange Commission on August 31, 2006.

QuickLinks

[EXPLANATORY NOTE](#)

[SIGNATURES](#)

[INDEX TO EXHIBITS](#)